PLSE
PULSE BIOSCIENCES, INC.
$24.37
-9.37%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders44 funds
Inst. Value$119.4M
Inst. Activity4 buys / 0 sells
Insider Activity4B / 7S
Insider Net $$23.7M
SEC Reports12
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001625101·Prev Close $26.89
Recent Activity
Jun 12, 2026
SEC
Four institutions increased PLSE positions in 2024-Q3, with Schwab nearly tripling its stake to $2.6M and Legal & Genera
INST-CLUSTER — Impact 6/10
Jun 10, 2026
SEC
Pulse Biosciences announced it will redeem the remaining 200% Warrants (exercise price $11.00) from its July 2024 rights
8-K — Impact 6/10
May 15, 2026
SEC
Two insiders at Pulse Biosciences, including CEO Paul LaViolette and director/10% owner Robert Duggan, made open-market
CLUSTER — Impact 7/10
May 11, 2026
Insider
DUGGAN ROBERT W bought 660,233 shares
Director @ $19.69 ($13.0M)
May 11, 2026
Insider
LAVIOLETTE PAUL A bought 15,000 shares
Chief Executive Officer @ $19.69 ($295.4K)
May 11, 2026
Insider
LAVIOLETTE PAUL A bought 15,000 shares
Chief Executive Officer @ $19.69 ($295.4K)
Inst.
CWM, LLC — DOUBLED
1,770 shares ($38.2K)
Inst.
NISA INVESTMENT ADVISORS, LLC — DOUBLED
52 shares ($1.1K)
Price Targets
$30.67
+25.8% upside
Strong Buy
Current $24.37
Low $30.00
Median $30.00
High $32.00
3 analysts
$30.00
$32.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | Canaccord Genuity | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.28 ▼ -18.7% | $-0.33 — $-0.24 | 2 | |
| Next Q | $-0.28 ▼ -18.7% | $-0.33 — $-0.24 | 2 | |
| Current FY | $-1.07 ▼ -17.6% | $-1.23 — $-0.91 | -42% YoY | 2 |
| Next FY | $-1.09 ▼ -23.9% | $-1.30 — $-0.88 | -2% YoY | 2 |
Latest Reports
BULLISH
INST-CLUSTER
6/10
Four institutions increased PLSE positions in 2024-Q3, with Schwab nearly tripling its stake to $2.6M and Legal & Genera
Jun 12, 2026
BULLISH
8-K
6/10
Pulse Biosciences announced it will redeem the remaining 200% Warrants (exercise price $11.00) from its July 2024 rights
Jun 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $28.9M | — |
| BANK OF AMERICA CORP | $18.7M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $17.6M | — |
| MASSACHUSETTS FINANCIAL SERVICES CO | $10.0M | — |
| STATE STREET CORP | $9.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | DUGGAN ROBERT | BUY | $13.0M |
| May 11, 2026 | LAVIOLETTE PAUL | BUY | $295.4K |
| May 11, 2026 | LAVIOLETTE PAUL | BUY | $295.4K |
| May 11, 2026 | DUGGAN ROBERT | BUY | $13.0M |
| Mar 23, 2026 | UECKER DARRIN | A | $0.00 |
44 institutional holders with $119.4M total value (5,550,032 shares) as of 2026-Q1. Top holders: BlackRock,, BANK, VANGUARD. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1,339,778 | $28.9M | 24.2% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 866,061 | $18.7M | 15.7% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 815,852 | $17.6M | 14.8% | — |
| 4 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 462,899 | $10.0M | 8.4% | — |
| 5 | STATE STREET CORP | 456,927 | $9.9M | 8.3% | — |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 265,164 | $5.7M | 4.8% | — |
| 7 | LMR Partners LLP | 213,137 | $4.6M | 3.9% | — |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 165,201 | $3.6M | 3.0% | — |
| 9 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 147,768 | $3.2M | 2.7% | DOUBLED +193.0% |
| 10 | CITADEL ADVISORS LLC | 142,150 | $3.1M | 2.6% | DOUBLED +176.3% |
| 11 | VANGUARD FIDUCIARY TRUST CO | 130,606 | $2.8M | 2.4% | — |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 81,252 | $1.8M | 1.5% | — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 54,000 | $1.2M | 1.0% | — |
| 14 | Nuveen, LLC | 45,435 | $980.9K | 0.8% | — |
| 15 | MORGAN STANLEY | 43,165 | $931.9K | 0.8% | TRIM -60.7% |
| 16 | GOLDMAN SACHS GROUP INC | 28,711 | $619.9K | 0.5% | — |
| 17 | TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC | 27,298 | $589.4K | 0.5% | — |
| 18 | DEUTSCHE BANK AG\ | 24,626 | $531.7K | 0.4% | — |
| 19 | ALLSTATE CORP | 23,468 | $506.7K | 0.4% | — |
| 20 | RHUMBLINE ADVISERS | 22,902 | $494.4K | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CWM, LLC | DOUBLED | 28 | 1,770 | +6221.4% | $38.2K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 26 | 52 | +100.0% | $1.1K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 17 | 44 | +158.8% | $950.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 11,231 | 14,859 | +32.3% | $321.00 | 2026-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 13,647 | 22,149 | +62.3% | $304.1K | 2025-Q4 |
| Allworth Financial LP | NEAR_EXIT | 170 | 17 | -90.0% | $234.00 | 2025-Q4 |
| CWM, LLC | TRIM | 51 | 23 | -54.9% | — | 2025-Q3 |
| UBS Group AG | ADD | 50,117 | 76,856 | +53.4% | $1.4M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 95,716 | 37,633 | -60.7% | $666.1K | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 13,433 | 37,118 | +176.3% | $657.0K | 2025-Q3 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 48,331 | 30,476 | -36.9% | $539.4K | 2025-Q3 |
| BARCLAYS PLC | TRIM | 34,648 | 25,488 | -26.4% | $451.1K | 2025-Q3 |
| Legal & General Group Plc | TRIM | 22,415 | 15,695 | -30.0% | $277.8K | 2025-Q3 |
| Russell Investments Group, Ltd. | ADD | 3,115 | 4,487 | +44.0% | $79.4K | 2025-Q3 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 1,322 | 500 | -62.2% | $8.8K | 2025-Q3 |
| Allworth Financial LP | DOUBLED | 8 | 170 | +2025.0% | $3.0K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 843,054 | 1,223,747 | +45.2% | $18.5M | 2025-Q2 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | ADD | 36,531 | 48,331 | +32.3% | $729.3K | 2025-Q2 |
| Legal & General Group Plc | ADD | 14,218 | 22,415 | +57.7% | $338.2K | 2025-Q2 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 30,890 | 19,670 | -36.3% | $296.8K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 1,246 | 19,338 | +1452.0% | $292.0K | 2025-Q2 |
| BARCLAYS PLC | ADD | 26,814 | 34,648 | +29.2% | $523.00 | 2025-Q2 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 70 | 26 | -62.9% | $392.00 | 2025-Q2 |
| UBS Group AG | ADD | 27,538 | 54,732 | +98.8% | $880.6K | 2025-Q1 |
| STRS OHIO | ADD | 9,500 | 17,800 | +87.4% | $286.4K | 2025-Q1 |
5 unique insiders with 21 transactions. Net insider value: $23.7M ($26.6M bought, $2.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | DUGGAN ROBERT W | Director | BUY | 660,233 | $19.69 | $13.0M |
| May 11, 2026 | LAVIOLETTE PAUL A | Chief Executive Officer | BUY | 15,000 | $19.69 | $295.4K |
| May 11, 2026 | LAVIOLETTE PAUL A | Chief Executive Officer | BUY | 15,000 | $19.69 | $295.4K |
| May 11, 2026 | DUGGAN ROBERT W | Director | BUY | 660,233 | $19.69 | $13.0M |
| Mar 23, 2026 | UECKER DARRIN | Chief Technology Officer | AWARD | 100,000 | — | — |
| Feb 18, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | EXERCISE | 5,000 | $1.53 | $7.7K |
| Feb 18, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | SELL | 5,000 | $23.64 | $118.2K |
| Feb 17, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | EXERCISE | 20,000 | $1.53 | $30.6K |
| Feb 17, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | SELL | 20,000 | $23.63 | $472.6K |
| Feb 13, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | EXERCISE | 20,000 | $1.53 | $30.6K |
| Feb 13, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | SELL | 20,000 | $23.53 | $470.6K |
| Feb 12, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | EXERCISE | 20,000 | $1.53 | $30.6K |
| Feb 12, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | SELL | 20,000 | $23.37 | $467.4K |
| Feb 11, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | SELL | 20,000 | $25.20 | $504.0K |
| Feb 11, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | EXERCISE | 20,000 | $1.53 | $30.6K |
| Feb 10, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | SELL | 20,000 | $23.52 | $470.4K |
| Feb 10, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | EXERCISE | 20,000 | $1.53 | $30.6K |
| Feb 9, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | SELL | 20,000 | $21.45 | $429.0K |
| Feb 9, 2026 | Danahy Kevin Patrick | Chief Commercial Officer | EXERCISE | 20,000 | $1.53 | $30.6K |
| Feb 5, 2026 | Sainz Maria | Director | AWARD | 3,104 | — | — |
| Jan 8, 2026 | Sainz Maria | Director | AWARD | 50,000 | — | — |
12 SEC filing reports analyzed. Sentiment: 7 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 5.5/10.
BULLISH
INST-CLUSTER
6/10
Four institutions increased PLSE positions in 2024-Q3, with Schwab nearly tripling its stake to $2.6
Jun 12, 2026
BULLISH
8-K
6/10
Pulse Biosciences announced it will redeem the remaining 200% Warrants (exercise price $11.00) from
Jun 10, 2026
BULLISH
CLUSTER
7/10
Two insiders at Pulse Biosciences, including CEO Paul LaViolette and director/10% owner Robert Dugga
May 15, 2026
BULLISH
CLUSTER
7/10
Two Pulse Biosciences insiders, including CEO Paul LaViolette and director/10% owner Robert Duggan,
May 12, 2026
BULLISH
CLUSTER
7/10
Two PLSE insiders, including CEO Paul LaViolette and Director Robert Duggan, collectively purchased
May 11, 2026
NEUTRAL
8-K
3/10
Pulse Biosciences disclosed that its Board authorized TD Cowen to sell common stock to company affil
May 6, 2026
MIXED
8-K
6/10
Pulse Biosciences reported Q1 2026 results with a GAAP net loss of $18.6M (-$0.27 EPS) that beat con
May 4, 2026
BULLISH
8-K
7/10
Pulse Biosciences presented positive late-breaking clinical data from its nPulse Cardiac Catheter Sy
Apr 27, 2026
NEUTRAL
8-K
3/10
Pulse Biosciences updated its investor presentation with new details about its pivotal clinical stud
Apr 16, 2026
NEUTRAL
8-K
3/10
Pulse Biosciences appointed Liane Teplitsky as Chief Operating Officer and expanded Dr. David Kenigs
Apr 9, 2026
BULLISH
8-K
7/10
Pulse Biosciences announced the first patient enrollment in its NANOPULSE-AF pivotal clinical study,
Apr 7, 2026
NEUTRAL
EFFECT
4/10
Pulse Biosciences, Inc. (PLSE) has received SEC effectiveness for a shelf registration (Form S-3), a
Mar 2, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$30.67 mean target
+25.8% upside
Strong Buy (1.00)
$30.00 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $24.37 |
| Target Low | $30.00 |
| Target Mean | $30.67 |
| Target Median | $30.00 |
| Target High | $32.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.28 | $-0.33 | $-0.24 | — | -18.7% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.28 | $-0.33 | $-0.24 | — | -18.7% | 0↑ 1↓ | $0.0B | 752.7% | 2 |
| Current FY 2026-12-31 |
$-1.07 | $-1.23 | $-0.91 | -41.8% | -17.6% | 0↑ 1↓ | $0.0B | 652.4% | 2 |
| Next FY 2027-12-31 |
$-1.09 | $-1.30 | $-0.88 | -1.9% | -23.9% | 0↑ 1↓ | $0.0B | 236.7% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.285 | |
| 7d ago | $-0.240 | -0.045 |
| 30d ago | $-0.240 | -0.045 |
| 60d ago | $-0.230 | -0.055 |
| 90d ago | $-0.230 | -0.055 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | Canaccord Genuity | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
PLSE Q1 2026 Earnings Scheduled — 2026-05-07
Apr 13, 2026
short_interest
FTD: PLSE — 27,116 shares ($0.5M) failed to deliver
Settlement: 20260413, Price: $18.67, FTD Value: $506,255.72, PULSE BIOSCIENCES INC COM (DE)
Apr 2, 2026
short_interest
FTD: PLSE — 23,040 shares ($0.5M) failed to deliver
Settlement: 20260402, Price: $23.03, FTD Value: $530,611.2, PULSE BIOSCIENCES INC COM (DE)
Mar 16, 2026
short_interest
FTD: PLSE — 47,748 shares ($1.0M) failed to deliver
Settlement: 20260316, Price: $21.57, FTD Value: $1,029,924.36, PULSE BIOSCIENCES INC COM (DE)
Feb 10, 2026
short_interest
FTD: PLSE — 97,044 shares ($2.3M) failed to deliver
Settlement: 20260210, Price: $24.21, FTD Value: $2,349,435.24, PULSE BIOSCIENCES INC COM (DE)